阿斯利康新冠肺炎在老年人试验中显示出希望

2020-11-19 15:26

AstraZeneca Covid-19 shot candidate shows promise among elderly in trials nt7世界播

阿斯利康新冠肺炎在老年人试验中显示出希望nt7世界播


暂无nt7世界播

Volunteers got two doses of the AZD1222 vaccine or a placebo, and no serious side effects were reported. nt7世界播

志愿者接种了两剂AZD1222疫苗或安慰剂,没有严重副作用的报道nt7世界播


LONDON (REUTERS) - A potential Covid-19 vaccine developed by AstraZeneca Plc and Oxford University produced a strong immune response in older adults, giving hope it may protect some of those most vulnerable to the disease, data from mid-stage trials showed. nt7世界播

伦敦(路透社)-中期试验的数据显示,阿斯利康(AstraZeneca Plc)和牛津大学(Oxford University)开发的一种潜在的新冠肺炎疫苗在老年人中产生了强烈的免疫反应,给人带来了希望,它可能会保护一些最容易感染这种疾病的人。nt7世界播


The data, reported in part last month but published in full in The Lancet medical journal on Thursday (Nov 19), suggest that those aged over 70 - who are at higher risk of serious illness and death from Covid-19 - could build robust immunity to the pandemic disease, researchers said. nt7世界播

研究人员表示,上个月部分报道了这些数据,但在周四(11月19日)的《柳叶刀》医学杂志上全文发表了这些数据,表明70岁以上的人患重病和死于新冠肺炎的风险更高,可以建立起对这种大流行性疾病的强大免疫力。nt7世界播


"The robust antibody and T-cell responses seen in older people in our study are encouraging," said Dr Maheshi Ramasamy, a consultant and a co-lead investigator at the Oxford Vaccine Group. nt7世界播

牛津疫苗集团的顾问兼联合首席研究员马赫希·拉马萨米博士说:“在我们的研究中,在老年人身上发现的强大抗体和T细胞反应令人鼓舞。”nt7世界播


"The populations at greatest risk of serious Covid-19 disease include people with existing health conditions and older adults. We hope that this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure." nt7世界播

“新冠肺炎严重患病的风险最大的人群包括既有健康状况的人和老年人。我们希望这意味着我们的疫苗将有助于保护社会上一些最脆弱的人群,但在我们确定之前,还需要进一步的研究。”nt7世界播


Late-stage, or Phase III, trials are ongoing to confirm the findings, researchers said, and to test whether the vaccine protects against infection with Sars-CoV-2 in a broad range of people, including people with underlying health conditions. nt7世界播

研究人员说,后期或第三阶段的试验正在进行中,以证实这一发现,并测试疫苗是否能在广泛的人群中预防感染SARS-CoV-2,包括有潜在健康状况的人。nt7世界播


The first efficacy data from those Phase III trials is "possible in the coming weeks", the Lancet report said. nt7世界播

柳叶刀的报告说,这些第三阶段试验的第一批疗效数据“可能在未来几周内”。nt7世界播


The Oxford-AstraZeneca Covid-19 vaccine candidate, called AZD1222 or ChAdOx1 nCoV-19, had been among the front-runners in global efforts to develop shots to protect against infection with the novel coronavirus, or Sars-CoV-2. nt7世界播

牛津-阿斯利康新冠肺炎候选疫苗名为AZD1222或ChAdOx1nCoV-19,在开发疫苗以防止感染新型冠状病毒(SARS-CoV-2)的全球努力中一直处于领先地位。nt7世界播


But rival drugmakers Pfizer Inc, BioNTech and Moderna Inc have in the past 10 days edged ahead, releasing data from late-stage Covid-19 vaccine trials that shows more than 90 per cent efficacy. nt7世界播

但竞争对手辉瑞公司(Pfizer Inc.)、生物技术公司(BioNTech)和现代公司(Modern na Inc.)在过去10天里略微领先,发布了晚期新冠肺炎疫苗试验的数据,显示出90%以上的疗效。nt7世界播


Unlike the Pfizer-BioNTech and Moderna shots, both of which use new technology known as messenger RNA (mRNA), the AstraZeneca experimental shot is viral vector vaccine made from a weakened version of a common cold virus found in chimpanzees. nt7世界播

与辉瑞生物科技和现代疫苗不同的是,这两种疫苗都使用了被称为信使RNA(MRNA)的新技术,而阿斯利康的实验疫苗是病毒载体疫苗,由在黑猩猩身上发现的普通感冒病毒的减毒版本制成。nt7世界播


The Phase II trial reported in The Lancet involved a total of 560 healthy volunteers, with 160 aged 18-55 years, 160 aged 56-69 years, and 240 aged 70 or over. nt7世界播

柳叶刀上报道的第二阶段试验共涉及560名健康志愿者,其中160名年龄在18-55岁,160名年龄在56-69岁,240名年龄在70岁或以上。nt7世界播


Volunteers got two doses of the vaccine or a placebo, and no serious side effects related to the AZD1222 vaccine were reported, the researchers said. nt7世界播

研究人员说,志愿者接种了两剂疫苗或安慰剂,没有与AZD1222疫苗相关的严重副作用报告。nt7世界播


AstraZeneca has signed several supply and manufacturing deals with companies and governments around the world as it gets close to reporting results of its late-stage trials. nt7世界播

阿斯利康(AstraZeneca)已与世界各地的公司和政府签署了几项供应和制造协议,该公司即将公布后期试验结果。nt7世界播

© 2016 世界播 www.shijiebobao.com 中国互联网举报中心 京ICP证140141号 鄂ICP备18018000号-1
违法和不良信息举报: